The Onco Life Podcast
Welcome to The Onco Life Podcast, your trusted source for cancer care insights, treatment updates, and patient-centered education. Hosted by the team at Onco Life Centre in Kuala Lumpur, Malaysia, this podcast is designed to guide patients, caregivers, and listeners through every stage of the cancer journey.
Each episode features expert advice from our oncologists, wellness tips, treatment innovations, and answers to the most common questions about cancer types, therapies, and recovery.
🎧 Empowering you with knowledge, support, and compassionate care—every step of the way.
📍 Kuala Lumpur, Malaysia
🌐 Learn more at oncolifecentre.com
The Onco Life Podcast
FDA Approves Zongertinib (Hernexeos): First Oral HER2-Targeted Therapy for Advanced NSCLC
In this episode, we break down the FDA’s historic approval of zongertinib (Hernexeos), the first oral HER2-targeted therapy for advanced non-small cell lung cancer (NSCLC) with HER2 mutations. This milestone offers patients and clinicians a long-awaited, convenient, and effective treatment option.
You’ll learn:
- Why have HER2-mutated NSCLC patients had limited options until now
- How zongertinib works differently from intravenous HER2 therapies
- Key results from the Beamion LUNG-1 clinical trial, including a 71% response rate
- The benefits of an oral, once-daily HER2 therapy for patients and doctors
- Safety, tolerability, and how zongertinib avoids common EGFR-related side effects
- Why this approval is a paradigm shift for precision oncology and rare cancer mutations
- The importance of routine molecular testing for NSCLC patients
This episode explores what the approval means for patients, oncologists, and the future of personalized lung cancer treatment.
Blog Link: FDA Approves Zongertinib: First Oral HER2 Therapy for Advanced NSCLC
Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.
Author: Dr. CHRISTINA NG VAN TZE
📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.